While the antigen(s) responsible for eliciting the sarcoidosis Th-1 immune response has not been identified (9, 13, 14) , reviews of sarcoidosis immunology and pathology suggest that mycobacterial antigens could be important (6, 8) . Previous studies have reported humoral responses to mycobacterial antigens among sarcoidosis subjects (4, 15) as well as the detection of mycobacterial nucleic acids and proteins in sarcoidosis granulomas (3, 5, 15) . We performed enzyme-linked immunospot (ELISPOT) assays to assess for cellular recognition of two Mycobacterium sp. antigens (ESAT-6, an immunodominant Tcell antigen present in some members of the Mycobacterium tuberculosis complex but absent in Mycobacterium bovis BCG [2] , and KatG, a catalase-peroxidase [7] ) from peripheral blood mononuclear cells (PBMC) from 26 sarcoidosis, 24 purifiedprotein-derivative-negative (PPDϪ), and 11 PPD-positive (PPDϩ) subjects.
This study was approved by the Vanderbilt University Institutional Review Board for human studies, and informed written consent was obtained from the study participants or their surrogates. All sarcoidosis subjects from the available patient database of the Vanderbilt University Pulmonary Clinic were invited to participate in the study. For inclusion in this study, the clinical, histological, and microbiologic criteria used to define sarcoidosis were as previously described (3). Healthy PPDϪ volunteers were required to have undergone PPD testing by the Vanderbilt employee health services. PPD-positive subjects had written documentation of their PPD statuses and had no evidence of active disease at the time of study enrollment.
The amino acid sequences for the 17 ESAT-6 peptides, 15-mers overlapping by 10 amino acids, were as previously described (11) . KatG peptides, 15-mers overlapping by 10 amino acids, were derived from the amino acid sequence of M. tuberculosis (GenBank accession number NP 216424) and are listed in Table 1 . Each ESAT-6 and KatG peptide was synthesized by solid-phase 9-fluorenylmethoxy carbonyl (Fmoc) chemistry (Genemed Synthesis, San Diego, CA), to a purity of Ͼ70%. Identity was confirmed by mass spectroscopy and purity by high-performance liquid chromatography. PBMC were isolated from blood samples drawn into tubes containing EDTA, separated by Ficoll-Hypaque density gradient separation (Amersham Biosciences), cryopreserved in fetal calf serum with 10% dimethyl sulfoxide, and stored in liquid nitrogen until the time of the analysis.
ELISPOT assays were performed as previously described (1) . The number of specific gamma interferon-secreting T cells was calculated by subtracting the mean negative-control value from the mean spot-forming-cell (SFC) count for duplicate wells inoculated with peptide. Negative controls always had Ͻ50 SFC per 10 6 input cells. A positive response was defined as a concentration of at least 50 SFC/10 6 PBMC that is at least three times higher than the background level. The research assistants were blind to the clinical diagnoses of the study participants throughout the analysis. Comparisons of distributions of T-cell frequencies were performed using the KruskalWallis test. Categorical comparisons were analyzed using Fisher's exact test. All P values are two sided and were determined using R (version 2.1.1). Sixty-one subjects were recruited for participation in the study. Of the 26 sarcoidosis subjects, 46% were African American, 42% were male, and 58% were 50 years of age or younger. Of the 24 PPDϪ patients, 33% were African American, 4% were Hispanic, 38% were male, and 88% were 50 years of age or younger (Table 2) . Of the 11 PPDϩ subjects (8 subjects with latent tuberculosis and 3 BCG vaccinees), 18% were African American, 9% Haitian, 18% Asian Indian, 27% male, and 72% 50 years of age or younger (Table 2) .
Among the 15 KatG peptides used in the ELISPOT assay, 13 of the 26 sarcoidosis subjects recognized KatG peptide 13 (codons 321 to 335) ( Table 2 ). None of the 24 PPDϪ or the 3 BCG-vaccinated subjects recognized any of the 15 peptides ( Table 2) . Seven of the eight subjects with latent tuberculosis infection ( Table 2 , PPDϩ 1 to 8) recognized KatG peptides 13 and 14 (codons 326 to 340). The immune recognition of KatG peptide 13 by 13 of 26 sarcoidosis subjects compared to that by 0 of 24 PPDϪ control subjects was statistically significant (P Ͻ 0.0001) ( Table 2 ). There was no significant difference between the results for sarcoidosis subjects and subjects with latent tuberculosis. We also compared the frequencies of KatG peptide 13-specific T cells in each group. Consistent with the above-described analysis, the T-cell frequencies for sarcoidosis subjects were higher than those for PPDϪ subjects (P Ͻ 0.0001) and lower than those for PPDϩ subjects, though the latter difference was not statistically significant (P ϭ 0.17) (Fig. 1) .
Of the 17 ESAT-6 peptides tested, there was recognition of ESAT-6 peptide 14 (NNALQNLARTISEAG) only. Eight of 26 sarcoidosis subjects, 1 of 24 control subjects (P ϭ 0.024), and 4 of 8 PPDϩ subjects (P ϭ 0.41) ( Table 2 ) recognized ESAT-6 peptide 14. While two of the sarcoidosis subjects recognized ESAT-6 peptide 14 only (Table 2 , sarcoidosis 9 and 13), six sarcoidosis subjects displayed immune recognition of both ESAT-6 peptide 14 and KatG peptide 13 ( Table 2 , sarcoidosis 1 to 6). Only one control subject recognized ESAT-6 peptide 14 ( Table 2 , control 1); the magnitude of this response was similar to that observed in the sarcoidosis and PPDϩ participants (Fig. 2) . The four PPDϩ subjects who recognized ESAT-6 peptide 14 also recognized KatG peptide 13 ( Table 2 , PPDϩ 1 to 4). There was no significant difference in the T-cell frequencies for ESAT-6 peptide 14 between the sarcoidosis and PPDϩ subjects (P ϭ 0.27) (Fig. 2) . The three subjects with BCG vaccination recognized none of the KatG or ESAT-6 peptides. All study participants exhibited strong responses to phytohemagglutinin. Overall, 15 of 26 (58%) sarcoidosis subjects recognized KatG peptide 13 or ESAT-6 peptide 14, compared to 1 of 24 (4%) PPDϪ subjects (P Ͻ 0.0001) and 7 of 8 PPDϩ subjects (P ϭ 0.21).
This study suggests for the first time that despite the negative culture and histology of sarcoidosis specimens, mycobac-FIG. 1. Distribution of T-cell frequencies for PPDϪ control, PPDϩ, and sarcoidosis subjects for KatG peptide 13. The bars represent the 25th percentile, median (50th percentile), and 75th percentile for each group; for PPDϪ controls, these three quantities are all equal to zero. The PPDϩ group included the greatest percentage of study participants recognizing KatG peptide 13 as well as the highest median T-cell frequency. Although the sarcoidosis subjects are PPDϪ and have no culture evidence of infection by mycobacteria, the distribution of the T-cell frequencies for the sarcoidosis subjects was significantly different from that for the PPDϪ controls (P Ͻ 0.0001) and was closer to that for the PPDϩ subjects (P ϭ 0.17).
FIG. 2.
Distribution of T-cell frequencies for the PPDϪ control, PPDϩ, and sarcoidosis subjects for ESAT-6 peptide 14. The bars represent the 25th percentile, median (50th percentile), and 75th percentile for each group; for PPDϪ controls, these three quantities are all equal to zero; for sarcoidosis subjects, the 25th percentiles and medians are both equal to zero. Although all of the sarcoidosis subjects tested were PPDϪ, there was a significant difference in the distribution of the T-cell frequencies for the sarcoidosis and PPDϪ subjects (P ϭ 0.024). The lone PPDϪ subject who recognized ESAT-6 peptide 14 had a T-cell frequency comparable to those for the sarcoidosis and PPDϩ subjects. Comparison of the sarcoidosis and PPDϩ subjects revealed that there was no significant difference in the distributions of the T-cell frequencies for ESAT-6 peptide 14 (P ϭ 0.27). (3) as well as the degree of an adaptive immune response to M. tuberculosis KatG proteins among sarcoidosis subjects previously reported in an independent study (15) . We did not assess for immune reactivity to the entire KatG protein sequence, so it is possible that other immunogenic peptides exist. The detection of immune recognition of ESAT-6 peptide 14 and KatG peptide 13 is unlikely to be secondary to that of nonspecific reactivity or exposure to routine environmental mycobacteria. First, no significant reactivity was observed among the PPDϪ control subjects, who live in the same region as the sarcoidosis and PPDϩ subjects. Second, ESAT-6 peptide 14 contains the amino acid sequence NNAL QNLARTISEAG, which has been previously reported to induce a CD8 ϩ T-cell response from tuberculosis patients (10). The absence of immune reactivity to ESAT-6 peptides by BCG-vaccinated subjects served as a good internal control for the specificity of the ELISPOT assay. M. bovis BCG does not contain esat-6 in its genome; thus, one would not expect to see immune reactivity to 15 ESAT-6 proteins among persons who had undergone BCG vaccination. These results support the hypothesis that mycobacterial antigens may have a role in sarcoidosis pathogenesis by demonstrating that they induce T-cell-antigen-specific Th-1 responses that are known to be important in sarcoidosis granuloma formation. This association does not imply causality but does provide another link between sarcoidosis and mycobacteria, supporting further investigation of the role of mycobacteria in sarcoidosis immunopathogenesis.
